论文部分内容阅读
目的：为了探讨肝癌瘤苗激活的肿瘤浸润性淋巴细胞（ＴＩＬ）对原发性肝癌（ＰＨＣ）患者血清可溶性白介素－２受体（ｓＩＬ－２Ｒ）的影响及意义。方法：使用冷冻方法制成肝癌瘤苗，用于激活ＴＩＬ。对２２例原发性肝癌患者使用经肝癌瘤苗激活的ＴＩＬ治疗，并应用双抗体夹心ＥＬＩＳＡ法检测治疗前后ｓＩＬ－２Ｒ水平变化以及与对照组相比较。结果：用经肝癌瘤苗激活的ＴＩＬ治疗者，其血清ｓＩＬ－２Ｒ水平下降幅度最大，用未经肝癌瘤苗激活的ＴＩＬ治疗者下降幅度次之，而未用ＴＩＬ治疗者下降幅度最小。结论：提示经肝癌瘤苗激活的ＴＩＬ能很快地解除原发性肝癌患者的免疫抑制，原因可能是由于它具有更强的杀伤体内残留的肿瘤细胞能力。
OBJECTIVE: To investigate the effect and significance of tumor-infiltrating lymphocytes (TIL) activated by hepatoma vaccine on serum soluble interleukin-2 receptor (sIL-2R) in primary liver cancer (PHC) patients. Methods: Hepatoma tumors were prepared using the freezing method for activation of TIL. TIL treatment was performed on 22 patients with primary liver cancer who were activated with liver cancer vaccines. The level of sIL-2R before and after treatment was detected by double antibody sandwich ELISA and compared with the control group. RESULTS: Serum sIL-2R levels decreased most significantly in patients treated with TIL treated with HCC tumors, followed by those with TIL that had not been activated with HCC tumors, and those with no TIL treatment had the smallest decrease. Conclusions: It is suggested that TIL activated by liver cancer vaccines can rapidly relieve immunosuppression in patients with primary liver cancer. This may be due to its stronger ability to kill residual tumor cells in vivo.